231 filings
Page 2 of 12
8-K
jsh 9yeoewhn5vt1smr
14 Jun 22
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
7:01am
8-K
hsirx sfxtwxot
27 Apr 22
Sio Gene Therapies Provides Corporate Update
4:35pm
8-K
l2bvwm31ltzcx1cm 0zj
18 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:21pm
8-K
91dt22b11tt1pop29g5
11 Feb 22
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
7:02am
8-K
thq73o4rssm l9
9 Feb 22
Regulation FD Disclosure
7:00am
8-K/A
ohft2tevjb4f9fee
31 Jan 22
Submission of Matters to a Vote of Security Holders
4:18pm
8-K
b96jqonmuopvo
31 Jan 22
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition
4:08pm
8-K
vyk4h
25 Jan 22
Departure of Directors or Certain Officers
4:50pm
8-K
an6efv 7ymma
12 Nov 21
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
7:02am
8-K
r4cka7
12 Nov 21
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy Program for Parkinson's Disease
12:00am
8-K
mnuscw1crimv4c84q 3k
1 Nov 21
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
7:00am
8-K
50ahu m69qi
21 Oct 21
Departure of Directors or Certain Officers
5:02pm
8-K
pj8s7u6
21 Oct 21
Regulation FD Disclosure
6:02am
S-8
lzchvyob a5q9r
6 Oct 21
Registration of securities for employees
5:18pm
8-K
a9v0 ng8w43n2u4h0
24 Sep 21
Departure of Directors or Certain Officers
4:09pm
8-K
clhur9ot0w8ql0 bw
12 Aug 21
Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results
7:22am